3 unchanged sentences
Number Description
−Removed: Executive Employment Agreement between the Company and Daniel Barber, effective on July 15, 2022.
+Added: License and Supply Agreement, dated as of September 26, 2022, by and between Aquestive Therapeutics, Inc.
+Added: and Atnahs Pharma UK Limited (filed herewith).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
11 unchanged sentences
104 Cover Page Interactive Data File (formatted as Inline XBRL document and contained in exhibit 101)
+Added: + Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been omitted.
+Added: The Company hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.
Table of Content
1 unchanged sentence
Aquestive Therapeutics, Inc.
−Removed: August 2, 2022 /s/ Daniel Barber
+Added: November 1, 2022 /s/ Daniel Barber
Daniel Barber
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 2, 2022 /s/ A.
+Added: November 1, 2022 /s/ A.
Ernest Toth, Jr.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.